B&W Equine Group has opened a brand new, state-of-the-art equine clinic at Breadstone in Gloucestershire.
The new facility opened on 1 October 2011. It cost over £2.2 million and is, according to the company, one Europe’s most advanced diagnostic and surgical centres.
B&W Equine Group was created in 2008, following a merger between Willesley Equine Clinic and Bushy Equine Vets. The 23 vet practice has four local equine clinics in Breadstone, Cardiff, Failand and Willesley.
The new clinic, located on a four acre site at Breadstone, close to the M4 and M5 intersections, provides state-of-the-art diagnostics and advanced laboratory facilities. It houses the only equine MRI scanner in Wales and the South West, as well as a CT scanner and scintigraphy unit. Orthopaedic and colic theatres, adult and neonatal intensive care suites and separate isolation units have all been custom-designed and are supported by five examination rooms and two knock down boxes.
Clinical and referral services are led by RCVS and European Recognised Specialists in surgery, orthopaedics, diagnostic imaging and internal medicine and include gynaecological management of breeding mares and pre-season disease screening. The on-site laboratory is one of only 30 in the UK to be certified by the HBLB to test for CEM and EVA.
Ian Camm, BVSc CertEP MRCVS, Group Director, said: “We are all extremely excited about the new clinic but our day-to-day first opinion work remains a top priority. For all our local clients it’s very much a case of business as usual but the fact that we have invested in the latest portable equipment, including video endoscopes, digital radiography and ultrasound scanners, means we can undertake more specialist work at client’s yards, as and when needed.”
For further information, visit www.bwequinevets.co.uk.
Dechra Veterinary Products, manufacturer and distributor of Equipalazone®, has launched a new website with up-to-date advice and guidance on the subject of equine pain management for horse owners: http://www.equinepainmatters.com/
Dechra says the website offers owners a place to go for information about pain in their horse including causes, diagnosis and the tools and techniques that their vet may use to treat pain. Owners will also be able to download anatomy charts and information leaflets on topics such as pain management, lameness, anaesthesia, sedation, euthanasia, the importance of microchipping and wound management.
Larry King, equine product manager at Dechra said: "This website is great for horse owners as they now have one place to go for information about equine pain matters. It will help them gain a better understanding of managing pain in their horses and the critical role that their vet plays in this area. Veterinary practices can also refer owners to it to support their consultation. This is the first website to put all this information together, so we are sure it will be popular.
"Cards with the new website address are available for practices to hand out to clients. "The website allows clients to browse the site in the comfort of their own home and is also ideal for practices with limited storage space for client information materials."
Dechra also encourages practices that have their own websites to link directly to www.equinepainmatters.com. Practices can order hand-out cards by contacting Dechra on 01743 441632 or email marketing@dechra.com.
CEVA Animal Health has produced a leaflet to help horse owners understand the diagnosis and treatment of navicular disease.
Navicular disease can be difficult to diagnose and management of the condition can be a challenge for both vets and horse owners. The new leaflet helps owners get to grips with all aspects of the disease from the clinical signs to the procedures used to obtain a formal diagnosis. It then covers the various treatment options available including corrective farriery, analgesia, bisphosphonates and surgery. Diagrams and photographs help to ensure that the information is clear, concise and easy to follow.
The leaflet is available to equine vet practices as a useful information source for clients. Please order your free copies from your CEVA sales representative.
The new Mars Equestrian Veterinary Research Scholar Programme offers the opportunity to conduct research alongside some internationally-renowned experts in equine health and veterinary welfare while pursuing two advanced credentials: the Graduate Certificate in Animal Welfare and Behavior at Penn Vet during year one, followed by the Master of Research (MRes) program at the RVC in year two.
The RVC says the new format offers an exclusive opportunity for the candidate to refine their critical research skills and expand animal welfare knowledge while learning on location at both the RVC in England and Penn Vet’s New Bolton Center in Kennett Square, Pennsylvania, United States.
The RVC’s MRes programme gives students the chance to develop into scientists who can work well across interdisciplinary teams, tackling problems of practical relevance to veterinary and medical science. Many of the courses’ graduates go on to work in some of the world’s leading scientific research institutes, as well as within industry and government.
Professor Richard Bomphrey, Interim Vice Principal for Research at the RVC said: “I am delighted that the RVC is able to support this new transatlantic initiative for veterinary graduates following a generous donation from Mars Equestrian. It strengthens the ties between the RVC, the University of Pennsylvania and Mars Equestrian while providing an outstanding training and research opportunity. We look forward to welcoming the successful scholar and helping them to make an impact in equine research."
The Veterinary Research Scholar program is open to interested UK, US and international candidates holding a veterinary degree (DVM/VMD/BVSc or equivalent). The chosen candidate will receive an annual stipend and tuition as well as travel expenses.
The programme will commence in September 2021 in the United States before moving to the UK in October 2022 until its conclusion in September 2023.
The deadline to submit applications for consideration is 30th June 2021 or until an acceptable candidate is identified.
Applications should be sent to the Penn Vet’s Dr. Kyla Ortved atkortved@vet.upenn.edu.
The Society for Practising Veterinary Surgeons (SPVS) has published its 2015 Fee Survey, which has revealed an increasing divergence between fees charged for routine and unroutine procedures in small animal practice.
SPVS says that small animal practices accounted for the largest proportion of responses to its survey, and that 75.9% of them had increased their fees during the last 12 months. When comparing a 'bundle' price comprising a kitten vaccination course, puppy vaccination course, cat spay, dog spay and consultation, the increase was 4.09%. However SPVS notes that this increase may be artificially low, as it relates to the sort of procedures that are regularly quoted and may therefore be constrained by the marketplace.
Perhaps more revealingly, whilst routine procedures such as vaccination had risen 3.3%, non routine procedures had risen by considerably more: pyometras were up 15.6%, cat dentals were up 17.5% and out-of-hours callouts were up 18.6%.
Equine fees showed an overall drop of 3.5% on the bundle price comprising initial routine examination, five-stage PPE, routine dental examination and float, a colic examination and the cost of sedation / waiting. Although many of the individual equine procedures showed a fee decrease, 79% of equine practices reported that they had increased fees over the past year. The largest decrease in equine fees was for sedating a horse and waiting while the horse was clipped or treated by an equine dental technician, with the fee charged being 12.5% less than last year and ranging from £12.50 to £93.82. Conversely, conducting an ultrasound scan of a mare for pregnancy had increased by 17.3% and ranged from £20 to £62.36.
For large animal vets, the fees are more tightly constrained by the commercial realities of farming and the range of fees quoted tends to be lower. This year, the overall price rise for the bundle of fees comprising routine calving, foot trimming, elective Caesarean and hourly rates for fertility work and herd health schemes was 4.1%. However, only 47.8% of large animal practices reported an increase in fees charged over the last twelve months. The largest increase reported was for paring the hind feet of a cow without sedation, which was up 24.4% and ranged in price from £19 to £70, while issuing a prescription to a farm animal client had decreased by 1.6% and ranged in price from 0 to £48.
Nick Stuart, SPVS president said: "We all know the industry is facing real challenges and this is reflected in the fee survey, with equine practices in particular decreasing many of their prices on last year. However the survey also shows that the fees vets charge vary widely, particularly in the small animal sector. While some of this can be accounted for by differing overheads, it does provide a fascinating insight into the various financial models that exist and challenges practice owners to review how they construct their fees. It also suggests that there is scope for practices to grow their profitability and understanding the market will help them with this.
"We have a new benchmarking service from Veterinary Insights that will help practices to set more accurate fee levels and we will be developing our fee survey further so that it dovetails with this service. I would urge practices to join SPVS and access the invaluable data we produce to help them grow their businesses."
For more information, a copy of the survey, or to join SPVS visit www.spvs.org.uk
CEVA Animal Health has published a trial which, according to the company, shows that horses suffering lameness caused by bone spavin can show marked improvement following treatment with a Tiludronate infusion, in combination with controlled exercise.
Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints which, says CEVA, is considered to be one of the most common forms of hindlimb lameness in the horse.
The double-blind, multicentric, placebo-controlled trials were carried out on a total of 108 pleasure horses, show jumpers and eventers of a variety of sizes and breeds, all of which had been clinically diagnosed with bone spavin. The horses were rigorously selected, having to show clinical signs of spontaneous lameness of at least six weeks but less than a year's duration and had to be in daily exercise. Horses suffering proximal suspensory desmitis were excluded.
Horses were defined as suffering from bone spavin if they displayed a chronic hindlimb lameness which improved with distal tarsal joint analgesia and showed radiographic evidence of bony changes associated with bone spavin in the distal tarsal joints. The horses were treated at day zero with a single Tiludronate infusion or a placebo and reassessed 60 days later after a period of controlled exercise.
Eighty seven horses completed the trials, comprising 42 Tiludronate treated horses and 45 placebo cases. By day 60 approximately 60% of the Tiludronate treated horses had improved in lameness by two grades or more, scored on a ten point system.
Horses with bone spavin experience abnormal bone remodeling changes, occasionally with excessive bone resorption in the tarsal bones. Tiludronate works by regulating this bone remodeling through a decrease in the resorptive process, slowing down the degradation of the bone structure when the condition is progressing and alleviating the pain associated with abnormal bone lysis.
CEVA has recently produced a leaflet specifically to help horse owners to understand the diagnosis and treatment of bone spavin. For copies of this leaflet and CEVA's comprehensive veterinary brochure on the product please contact CEVA Animal Health on 01494 781510 or visit the website at http://www.tildren.com/
Tiludronate infusion in the treatment of bone spavin: A double blind placebo-controlled trial
Reference M. R. GOUGH*, D. THIBAUD† and R. K. W. SMITH‡ (*CEVA Animal Health, Bucks, UK; †CEVA Animal Health USA, Kansas, USA; and ‡Department of Veterinary Clinical Sciences, The Royal Veterinary College, University of London, UK). Equine vet. J. (2010) 42 (5) 381-387 doi: 10.1111/j.2042-3306.2010.00120.x
The term ‘evidence synthesis’ describes a range of methodological approaches used to systematically review, appraise, and summarise evidence on a specific area.
The approaches differ from conventional literature reviews or narrative reviews, which are not required to have a specified search strategy or methodology for appraising evidence, and usually present a personal perspective or opinion.
There are three main types of evidence syntheses: rapid reviews, systematic reviews, and scoping reviews.
All have key principles in common, which includes the formulation of a structured question, a systematic search of the available literature, a defined process of reviewing and selecting suitable publications, and a methodology for analysing the final included evidence.
Evidence synthesis is still not widely used in the equine veterinary world, despite its recognised value in human evidence-based medicine.
In the new virtual collection, the EVJ discusses the what and the why of this important evaluation method, as well as providing free access to all the equine veterinary evidence reviews published to date, including:
“Evidence synthesis makes an important contribution towards generating the evidence base which underpins equine clinical practice,” said Professor Sarah Freeman. “The challenge compared to human medicine is that equine veterinary data sets are much smaller, and study approaches and methodologies often vary significantly which means that it may not be possible to combine or collate data sets.
“Given this shortfall, scoping reviews can be helpful to identify what information is out there, find areas where a systematic review could be performed, and provide a useful summary for all the studies in a particular area.”
Professor Celia Marr, Editor of the EVJ said: “As increasing numbers of evidence syntheses are published, they will expand our understanding of the current bodies of evidence in veterinary medicine.
“The existing studies are already informing us on how we use evidence in our practices and policies, and it is encouraging to anticipate how they will shape our development of future research, to generate the best evidence as the norm, in every case.”
The virtual issue can be found at https://beva.onlinelibrary.wiley.com/doi/toc/10.1001/(ISSN)2042-3306.evidence-synthesis-collection
Research published in EVE by Pearson in 2020 reported that 95% of equine vets work with “difficult” horses on at least a monthly basis, and that 81% of them had sustained at least one injury in the last 5 years.
The research also indicated that some vets overestimate their understanding of equine learning theory.
The BEVA says developing an extended understanding of how horses learn can make clinical care less stressful, and that reduced patient stress also improves workplace safety, which is important in a role that has been identified as one of the most dangerous civilian professions.
Gemma said: “Horses have limited cognitive skills and so we should try to better understand what motivates and reinforces unwanted behaviours rather than assuming the horse is being wilfully or maliciously disobedient.
“To do this we need to appreciate how horses learn.
"Better horse handling leads to happier horses, and this means happier vets and nurses and owners/clients with the ultimate knock on of better safety, better job satisfaction and better retention in the profession.”
The training sessions include:
Gemma added: “One of the biggest push backs I get from people that haven’t started to develop low stress vet care as a routine is that they haven’t got time. But those who do use it say that it saves them time and keeps them safer, this also brings obvious commercial benefit to the practice - so what’s not to like?”
https://www.beva.org.uk/elearning-redirect?redirect=/course/view.php?id=622
The Royal Veterinary College and the Animal Health Trust are trying to recruit 3000 horse and pony owners to take part in 'CARE about laminitis', a web-based research project that aims to reduce the threat caused by laminitis.
The four-year study, which is being funded by World Horse Welfare, is being conducted by PhD student, Danica (Dee) Pollard, based at the AHT. The main aims of the study are to:
Currently the veterinary-reported frequency of laminitis in Britain, estimated between 2009 and 2011, shows that active episodes of veterinary-diagnosed laminitis occurred in nearly 1 in 200 horses/ponies registered with veterinary practices, and accounted for nearly 1 in 200 equine visits. Dee said: "However an overall lack of studies into the frequency of laminitis leaves little to compare these estimates with."
If you'd like to take part in the study, or invite clients to do so, visit: www.careaboutlaminitis.org.uk or email danica.pollard@aht.org.uk.
All existing BEVA members will have their membership automatically extended until 30 June 2020. The association is also inviting vets and vet nurses who are not already BEVA members to join as online members free of charge until 30 June 2020.
BEVA President Tim Mair said: “In this extraordinary time of global crisis our profession, as with many industries, is under immense pressure. By offering free membership we are giving equine vets easy access to a wealth of supportive resources and online CPD to help them through these dark times.”
BEVA membership includes:
The association is also looking at other ways to support the profession, which has included making all BEVA Congress 2019 webinars available to members via the BEVA online learning platform.
To sign up from Monday 30 March 2020 visit: https://www.beva.org.uk/Join-BEVA
Fort Dodge Animal Health has announced it is working with the authorities to put measures in place to make its West Nile Virus vaccine, licensed in the United States, available to the European equine market. These measures will ensure a vaccine is readily available in the event of an outbreak in the UK.
This news comes as the Zooprophylactic Institute of Teramo, the Italian National Reference Centre for Exotic Diseases, has confirmed an outbreak of WNV among horses in stables in the northern province of Ferrara. About 20 horses are believed to have been affected.
Fort Dodge was the first company to develop and fully license a vaccine to protect horses against this potentially deadly disease. An inactivated whole virus vaccine, it was the only vaccine available in the United States at the height of the 2002 outbreak, which affected 15,000 horses. The U.S. Department of Agriculture credited the vaccine with contributing to the 70 per cent decline in U.S. equine West Nile cases since the height of the outbreak. WNV is now considered endemic in all areas of North America.
"As this latest outbreak of WNV in Italy highlights, the disease presents an increasing threat to the equestrian sector in Europe," says Helen Barnes, EMEA Equine Business Manager for Fort Dodge. "With little current natural immunity among the equine population, the consequences of a major outbreak could be devastating."
"Until now, horse owners in Europe have perhaps believed WNV is not a disease they should be concerned with but the outbreak in Ferrara came out of the blue, and at a time when a human case of WNV was also reported in the same province. This situation of both human and equine cases being reported is identical to that seen in the outbreaks in the United States. It's a stark reminder of the challenge this disease poses, particularly as environmental factors, such as global warming and heavy rains threaten to create mass breeding grounds for mosquitoes," says Barnes.
"Our experience with WNV in the United States has given us an exceptional understanding of the disease and the importance of vaccination. We now look forward to working in partnership with the European governments, the EU Commission and the veterinary community across Europe to help build understanding and knowledge of this dangerous emerging disease threat."
Intervet/Schering-Plough has launched Vectin chewable tablets, an ivermectin wormer for horses which is administered as a treat straight from the hand rather than in the traditional paste or granule formulation.
According to the company, syringe handling, horse acceptance and the tendency to spit out some or all of the paste are common problems reported by owners when worming their horses, and more than 55% admit that these issues can result in a mixture of emotions, including frustration, anxiety and upset.
Field studies with Vectin showed more than 70% spontaneous acceptance by horses and the simple calculation of one tablet for every 110kg of a horse or foal's bodyweight helps to reduce wastage as unused tablets can be stored away for future use.
Pharmacokinetics studies have demonstrated improved bioavailability (AUC) and maximal concentration (Cmax) when compared with an equivalent competitor ivermectin paste formulation. Trials have also shown that a more consistent blood concentration of ivermectin when given as a chew which could potentially limit the chance of inducing resistance.
Intervet/Schering Plough says that used as part of a strategic worming plan, Vectin chewable tablets control potentially a wide range of endoparasites including small and large strongyles, stomach worms, cutaneous worms and stomach bots.
Vectin chewable tablets are available as a seven-tablet blister pack, perfect for treating a horse or a couple of ponies. For yards, a tub of 60 tablets is available, containing enough to dispense product for worming approximately 12 horses.
Vectin chewable tablets are recommended for use alongside Pyratape P and Panacur in Intervet/Schering-Plough Animal Health's Active3 worming plan, a strategic three-year approach to rotating wormers in order to minimize the risk of resistance developing. Visit http://www.intervet.co.uk/ for a copy of the three-year plan.
BCF Technology has launched a competition to win a top of the range digital radiography system from its Cuattro range for 6 months.
To enter the competition, you need to record a short video (up to 2 minutes) explaining how the DR system would transform your imaging function. BCF is asking entrants to be as creative as possible as the voting will be open to the public. The company will pick a shortlist of finalists and then invite the public to vote for a winner on its Facebook page and website.
The competition is open to both small animal and equine vets, for the following systems:
Sarah O'Grady from BCF said: "Having a Cuattro DR system could make a huge difference to either a small animal or an equine practice. For a small animal vet practice that doesn't currently have a DR system, they will love the difference it makes to X-ray studies. Diagnostic images are produced in seconds and re-takes are almost non-existent. A Wireless Slate 3+ can greatly improve the ease of in-stable operations and procedures. With the removal of wires, these procedures run much smoother. You will also be surprised by the improvement in image quality."
The closing date for the competition is 30th November 2013.
To enter your video:
The winner will be required to arrange insurance for the system during the time they have the system. Full terms and conditions can be found on the BCF website.
To find out more visit the BCF website or Facebook page or call +44 (0)1506 460 023.
Participation in this year’s survey was similar to previous years with 5,235 people taking part and returning records for 15,433 horses. Most horses were kept in livery or a private yard and used for leisure and hacking and the majority within the age range of 5 to 10 years.
A broad variety of breeds were represented, including natives, thoroughbred types and warmbloods.
59% of horses were recorded as healthy and 41% with one or more health problems, compared to 62% and 38% respectively in 2016.
The top five disease syndromes recorded this year were:
Of the 5.5% of horses recorded with back problems 26% were also showing signs of lameness. While the details of the results do not confirm that the two are necessarily connected, these findings reflect the outcome of recent studies conducted by Dr Sue Dyson, Head of Clinical Orthopaedics at the Centre for Equine Studies at the Animal Health Trust.
Sue said: "It is a common observation that horses with lameness stiffen the back as a protective mechanism and develop muscle pain which may be misinterpreted as a primary back problem. We have shown objectively that abolition of lameness by diagnostic analgesia results in an immediate increase in range of motion of the back. The current data supports this close relationship between lameness and back pain."
A new study published this month in the Equine Veterinary Journal (EVJ)1 has concluded that toxins from the seeds of the sycamore tree (Acer pseudoplatanus) are the likely cause of Atypical Myopathy (AM) in Europe.
However, to avoid confusion, the authors of the study point out that the American Sycamore (also just called 'the sycamore' in the USA), is a completely different species: Platanus occidentalis. Furthermore, the sycamore found in the UK is also known as the sycamore maple in other countries.
The new research follows on the heels of a study in the USA earlier this year that linked toxins from the box elder tree (Acer negundo) with Seasonal Pasture Myopathy (SPM), the US equivalent of AM2. The discovery marks an important step for the future prevention of this fatal disease.
Atypical Myopathy is a highly fatal muscle disease in the UK and Northern Europe. In ten years, approximately twenty European countries have reported the disease. Incidences tend to occur repeatedly in the autumn and in the spring following large autumnal outbreaks. Horses that develop AM are usually kept in sparse pastures with an accumulation of dead leaves, dead wood and trees in or around the pasture and are often not fed any supplementary hay or feed. SPM is a very similar disorder, prevalent in Midwestern USA and Eastern Canada that is now known to be caused by the ingestion of hypoglycin A, contained in seeds from the box elder tree.
The new European research1 was conducted by an international team led by Dominic Votion, University of Liege and involved 17 horses from Belgium, Germany and The Netherlands, suffering from Atypical Myopathy. High concentrations of a toxic metabolite of hypoglycin A, were identified in the serum of all of the horses. The pastures of 12 of the horses were visited by experienced botanists and the Acer pseudoplatanus, the sycamore maple, was found to be present in every case. This was the only tree common to all visited pastures.
Researchers believe hypoglycin A is the likely cause of both AM in Europe and SPM in North America. The sycamore and the box elder are known to produce seeds containing hypoglycin A and the pastures of the afflicted horses in Europe and the USA were surrounded by these trees.
Hypoglycin-A is found in various levels in the seeds of plants in the genus Acer as well as in various other genera in the family Sapindaceae such as ackee (Blighia sapida). In ackee, hypoglycin-A levels do vary with ripeness of the fruit and, if the fruit is eaten before it is mature, it causes hypoglycaemia to different degrees including a condition called "Jamaican vomiting sickness" (because of ackee's use in Jamaican cooking) and occasionally death in humans.
Researchers at the Universities of Minnesota2 and Liege are continuing their work to try to uncover exactly how the equine disease occurs. Dr Adrian Hegeman of University of Minnesota said: "It is likely that the most important contributing factors to horses becoming poisoned by hypoglycin-A are the availability of seed in the field combined with lack of other feeding options. The seeds from two species of maples (box elder and sycamore maples) that we have tested include significant quantities of hypoglycin-A.
"We know that seeds contain highly variable quantities from seed to seed, even within a single tree. We do not know yet how hypoglycin-A levels vary seasonally, nor do we know how its abundance varies with different levels of stress to the plant, though this may well explain seasonal variability in the occurrence of the malady. It is possible that conditions that stress the plants may contribute to significant seasonal changes in hypoglycin-A levels. At this point we just don't know. It is common held knowledge that trees under stress usually produce more seed."
Dr Jeff Gillman of University of Minnesota said: "Without question, further analysis of the seeds and other tissues from Acer species needs to be performed along with sampling of plant materials over multiple seasons and at various stress levels. Additionally, one cannot rule out more complex explanations for the seasonality of disease occurrence such as: animals may begin feeding on seed materials in response to depletion of more palatable choices under drought conditions; or simple explanations such as high wind events driving seeds into fields. These sorts of explanations for the occurrence of the disease do not depend on botanical variations in toxicity across seasons, sites or stress levels, yet also require consideration.
"Although limited examples are available, the experience of animals at a pasture site might also confer some degree of behavioral resistance to poisoning due to exposure at sub-lethal levels with prior exposure to seeds in the pasture."
Professor Celia Marr, Editor of Equine Veterinary Journal said: "This is an important advancement in our understanding of what causes AM and how it can be prevented. In immediate practical terms owners can take prompt measures to avoid exposing their horses to sycamore seeds this autumn. Where horses are grazing in the vicinity of sycamore trees, it is imperative that they are provided with sufficient supplementary feed as this will minimise the risk that horses might be tempted to ingest seeds containing this toxin. This must be done carefully and leaving wet hay on the ground should be avoided so providing extra carbohydrate feeds may be more practical."
References
Pfizer Animal Health, maker of the equine wormers Equest and Equest Pramox, has unveiled www.wormingyourhorse.info, a new website which aims to make it easier for horse owners to understand and follow the most up-to-date principles of sustainable worm control.
Based on the company's Manage, Test, Plan, Dose campaign, Pfizer says the new website is designed to take the confusion out of equine worm control with clear, logical and easy-to-understand guidance and advice.
The four main sections use diagrams and text to explain how and why it's important to manage the worm challenge on the pasture; the role of faecal worm egg counts (FWECs); how history and management play a part in planning the best worm control programme and how to choose and use the right wormer at the right time of year.
There's an interactive and educational parasite page that shows the parasites that can affect the health of your horse. There are click through buttons on parts of the horse's anatomy revealing details about the appearance of each particular parasite, their lifecycle and the symptoms they can cause. In addition there's a section on frequently asked questions which provides no-nonsense answers to some of the most commonly asked questions about worm control.
Paul Blanc, Pfizer's equine brand manager said: "In developing our new website we have listened carefully to what horse owners really want and need to know. The result is a source of plain-speaking, unbiased facts and advice, providing horse owners with the most current thinking on sustainable worm control in a format they can really identify with."
The aim of the week is to focus equine practices on ‘Taking care of the small things that make a big difference’ with a toolkit of resources designed to help them promote their businesses and educate and promote the benefits of preventative healthcare.
Peter Young, MSD Equine Business Manager said: "This year’s Horse Health Week has been created to focus on the small things we can all do to help keep our nation’s horses happy and healthy. We are encouraging equine vets to get involved and engage with their clients throughout the week with the support of our toolkit. This celebration of Britain’s horses and the things we can do to improve their health is a positive opportunity for vets to build client loyalty and attract new clients. I urge practices to do as little or as much as they can, but I urge them to do something!"
Horse Health Week is supported with a range of materials for both practices and clients, along with social media content, which vets can obtain on a USB stick from their MSD Animal Health Equine representative.
The toolkit includes a series of five animations – one for each day of the week. They each cover a different topic including; horse connections, the importance of hand washing, equipment at shows, isolation and vaccination. There is also a social media campaign for practices to run called #BonVoyageBuzz, and a survey that will gather the views of horse owners on preventative healthcare.
For full details talk to your MSD Animal Health Account Manager, call MSD on 01908 685685 or refer to www.healthyhorses.co.uk/horse-week.
VetSurgeon member Viki Edmondson MRCVS is taking part in a drive to help 13-year-old Octavia Woodward, who was born with spinal muscular atrophy (SMA), raise £100,000 to help The SMA Trust.
Viki, a well-known vet in the carriage driving world, will be joining Octavia on 'Octavia's Mad Marathon', a five-day, 110 mile carriage drive from Windsor to Wincanton.
Octavia will be driving her pony, Diddy, with her mother Henrietta as co-driver. Meanwhile, Viki will be driving a pair of Gelderlander horses. They'll be leaving the main ring at the Royal Windsor Horse Show with a support crew at 3:30pm on 13th May.
Viki graduated from Bristol Veterinary School in 1993. Since 2001 she has run her own equine practice plus a small animal surgery from the Newdigate, Surrey farm she shares with husband Peter. Viki has known Octavia since she was born and it was Viki who paired up Diddy with Octavia and encouraged her to progress from walking round the roads to the excitement of "off-roading". Viki will be providing support and encouragement to Octavia during the trip - of course with any veterinary help being close by.
To support Viki and Octavia, visit: http://www.justgiving.com/vikithevet
Three bursaries are available - two in ruminant and one in companion animal research, each worth up to £4,000.
Annabelle Mohring, Veterinary Advisor at MSD Animal Health said: "We appreciate that the last 18 months have been challenging for many veterinary surgeons and adding new research to this may not be considered a priority. But with the pace of change rapidly increasing, improving business skills and scientific knowledge will become more important than ever for the profession.
"Research forms the foundation of the industry and being awarded a bursary has proved to be a career-changing experience for some participants. We're now welcoming applications as part of our investment in the veterinary community."
Each project should be completed within one to two years and the veterinary surgeon proposals will be judged by objective third party university academics to ensure independent assessment.
The deadline for the MSD Animal Health Veterinary Surgeon Research Bursaries is 30th November 2021.
For further information, visit: www.msdahresearchbursary.co.uk.
Photo: Hattie Barnes who was awarded the 2020 Veterinary Surgeon Bursary in the companion animal sector. She was awarded £4,000 for her analytical, cadaver-based study to investigate different draping protocols in elective orthopaedic surgery. Hattie is currently undertaking a 3-year residency in Equine Surgery at the University of Liverpool.
Boehringer Ingelheim has announced that its 'Talk About Laminitis' campaign will run from Mid March until the end of June.
Last year, the initiative saw over 9000 horses and ponies tested for PPID through its free ACTH test scheme. This year, to build on this success and support the testing of even more animals, the company has announced a high impact, co-ordinated campaign to drive awareness that up to 90% of laminitis cases may have an underlying endocrine cause1,2.
Once again, Boehringer is urging veterinary surgeons to carry out free ACTH blood tests on laminitic or foot-sore horses as part of the campaign, which is backed by Redwings, The British Horse Society and World Horse Welfare.
Professor Andy Durham from the Liphook Equine Hospital, where the ACTH tests are performed, said: "We are learning so much from these tests. For example, we are now recognising PPID routinely in laminitic horses and ponies as young as 10 years old, and in the spring when we might expect to see more EMS cases, where veterinary surgeons have also tested for PPID we are seeing both abnormally elevated ACTH and insulin. Unless the PPID is addressed, horses will continue to be at risk of painful recurrent laminitic episodes which is a significant welfare issue to the horse and extremely frustrating for owners."
To participate in the scheme, veterinary surgeons and horse owners can download ACTH blood test vouchers from www.talkaboutlaminitis.co.uk. Attach the voucher to the ACTH sample submission form and the ACTH laboratory fees will not be charged.
Lee Hackett from The British Horse Society said: "Without the 'Talk About Laminitis' initiative and the support of Boehringer Ingelheim, literally thousands of horses may not be receiving the appropriate treatment and management for their laminitis to help prevent recurrence. We hope as many veterinary surgeons as possible get involved this year to continue this welfare success."
To ensure that horse owners are fully aware of the initiative, a PR and advertising campaign in the equine consumer media will start in March. The ad campaign includes an infomercial on Horse & Country TV (SKY Channel 280), with viewer numbers in excess of 450,000 per month.
There will also be a live online broadcast for horse owners on endocrinopathic laminitis presented by David Rendle BVSc MVM CertEM(IntMed) DipECEIM MRCVS, from the Liphook Equine Hospital in Hampshire. The one-hour webinar, which takes place at 8.00pm on Wednesday 10 April, will educate horse owners on how the veterinary profession's understanding of this debilitating and devastating disease has been completely revolutionised over the past five years. It will be followed by an interactive Q&A session when viewers will be able to pose questions for David to answer.
David said: "As our knowledge of the two hormonal diseases responsible for the majority of cases of laminitis improves, veterinary surgeons can offer their clients more comprehensive advice on treatment options to prevent laminitis. For many owners who have struggled with this condition, this is an absolute revelation and has enormous welfare benefits".
Horse owners can register to view the online programme by visiting www.talkaboutlaminitis.co.uk.
To ensure that veterinary surgeons are versed in the most up to date research available, Boehringer Ingelheim will also be hosting a webinar for veterinary professionals at 8.00pm on Wednesday 13th March, presented by Professor Andy Durham BSc BVSc CertEP DEIM DipECEIM MRCVS. The online seminar, 'The laminitis revolution.... An update on our understanding of endocrinopathic causes of laminitis', will entitle the viewer to a downloadable certificate for one hour of CPD. To register, visit www.bi-academy.co.uk. Places are limited, so register early to avoid disappointment. The webinar will also be available to view after the event on demand.
For further information on how you can promote 'Talk About Laminitis' in your practice contact your Boehringer Ingelheim Territory Manager or call 01344 746959
1. Karikoski et al. (2011). The prevalence of endocrinopathic laminitis among horses presented for laminitis at a first-opinion/referral equine hospital. Domestic Animal Endocrinology 41 111-117
2. Donaldson et al. (2004). Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis. J Am Vet Med Assoc;224:1123-1127.
Researchers at the University of Edinburgh’s Royal (Dick) School of Veterinary Studies are to start testing whether a compound of cooling chemicals, extracted from mint, can be used to treat laminitis, a condition which affects seven per cent of the British horse population.
The new project, funded by The Horse Trust and led by Professor Sue Fleetwood-Walker, builds on recent work that revealed for the first time that, there is significant nerve damage, as well as inflammation, within the hoof of laminitic horses. This explains why anti-inflammatory drugs are so ineffective in treating the pain of chronic laminitis and highlights the need for therapies to treat nerve injury-induced or ‘neuropathic’ pain in horses.
Prof Fleetwood-Walker’s team discovered in 2006 that the ‘mint’ chemicals have a pain–killing effect in laboratory studies of chronic pain. They will now investigate whether this synthetic treatment could help horses with laminitis.
Bruce Bladon will describe current antibiotic use in equine practice, Victoria South will consider the use of Highest Priority Critically Important Antimicrobials, and Bettina Dunkel will describe strategies to reduce antimicrobial use.
The webinar is free for both members and non-members.
To register, visit: https://us02web.zoom.us/webinar/register/7016678281618/WN__XNTbcxoQ2K1mXUGOIVL_g
Photo: Safia Barakzai, Equine Surgeon
BEVA Congress 2021 will now take place from September 4th-7th 2021.
The decision to cancel Congress 2020 was taken by BEVA Council and the Congress programme committee because of the unpredictable circumstances of the coronavirus pandemic.
Tim Mair, President of BEVA said: “The overriding factor in our decision-making process was to protect everyone attending Congress. We are chartering unknown territory at the moment and the additional planning requirements needed to run a large event like BEVA Congress with social distancing measures in place will take time.
“We intend for September 2021 to mark an exciting, fresh start for the profession following the harrowing experiences of 2020. It should be safe for our international speakers and delegates to attend by then, getting us all back on track with networking and world-class CPD to inspire us for the new post Covid-19 world.”
Tickets for BEVA Congress 2021 will be available later this year, more information from: www.bevacongress.org.
Zoetis Business Consulting has released figures showing that Profit Solver, its financial analysis tool, has delivered an average EBITDA (earnings before interest, taxes, depreciation and amortization) growth of 36% for the 28 UK practices that have used the new service since its launch.
Profit Solver was first launched in the USA, where the company says more than 300 practices have now benefited from the service.
Zoetis says that traditionally, veterinary practices have set their prices by simply adding a set mark-up, without knowing which services make a profit or loss and without understanding exactly how overall practice profit is being generated.
Profit Solver instead uses the practice’s own data to calculate the exact cost for the 130 most commonly performed veterinary services, representing 90% of the revenue generated by the practice. It then combines labour, inventory and equipment costs with time-and-motion studies for each service, and assesses the variance between cost and price to reveal profit or loss.
By using a collection of cost data, which staff perform which part of the procedure, how long the procedure takes and what equipment and materials are used, Profit Solver calculates the correct pricing to both cover costs and deliver a pre-determined profit margin.
Implementing Profit Solver is done with a Zoetis business consultant who guides the practice through the process, from data collection to examining the time-and-motion studies. They discuss the level of profitability the practice needs to deliver and help analyse prices to achieve this goal whilst preserving the price-point of highly competitive services and covering all the practice’s costs.
Ian Camm, Group Director of B&W Equine Vets in Gloucestershire heard about Profit Solver from a vet in a neighbouring practice who was impressed with how it had helped his business. Ian discussed Profit Solver with his Zoetis account manager and booked an appointment with Zoetis Business Consultant Anthea Pike who has helped him implement the software across B&W Equine Group.
He said: "Initially I was concerned that Profit Solver would suggest we put prices up where we felt that we would not be able to - people shop around for their veterinary services these days and many services are very price sensitive. The first stage in the process addressed this by looking at our figures, calculating the cost price for each procedure and then, by comparing with our fees charged, identified where we were losing money. The big question was whether we would be comfortable to increase our fees on loss-making procedures. The beauty of the system was that by looking at a large number of procedures which were done frequently, very small increases in fee would total to a significant improvement in the bottom line.
"The software has made us recognise where the real costs are and how to address these areas accordingly, for example we have identified that current stud packages are not profitable. One of the problems in arriving at true costs is the difficulty in accurately allocating time to various procedures when several different vets are involved or an expensive scanner is used, which can have a significant impact on the results. It’s early days, but I can already see the difference that Profit Solver could make to our bottom line and wouldn’t hesitate to recommend it providing the practice is prepared to make changes in light of the results. We are looking at improving our bottom line by a six figure sum over a 12 month period with what we hope, will be hardly noticeable price rises.”
For further information visit www.zoetis.co.uk/businessconsulting.
Merial has announced the UK launch of updated ProteqFlu, the first and only EI vaccine in Europe to contain a clade 2 strain.
The company says the new vaccine is also the only one that is fully compliant with the latest 2014 OIE recommended EIV strains.
Louise Radford MRCVS from Merial said: "The launch marks the UK's first and only fully updated equine flu vaccine that contains both a Clade 1 and Clade 2 antigen which includes protection against the latest Florida Clade 2 strain, Richmond 07. This is a significant step for horse health, and the equine industry as a whole."
Hervé Poulet, Merial's head of BioDevelopment and BioResearch said: "Merial has developed strong and unique expertise in the development of non-replicative recombinant canarypox virus-vectored vaccines for various species and diseases.
"For the development of ProteqFlu, our non-replicative recombinant canarypox vector expressing the EI virus haemagglutinin (HA) is used because of its ability to induce a strong cellular immunity which is an essential component in protecting against this highly contagious disease."
Louise added: "ProteqFlu has also demonstrated its success and efficacy in real outbreaks, particularly during the last major outbreak, in Australia in 2007. ProteqFlu was the only vaccine chosen for the eradication programme."